Cargando…

Predictive Factors for High Post-void Residual Volume in Older Females After OnabotulinumA Treatment for Severe Overactive Bladder Using a Machine Learning Model

Introduction Intravesical onabotulinumA injection is actively used for the treatment of overactive bladder (OAB). However, it occasionally results in significant post-void residual urine (PVR) volume, which can lead to complications and can further impair the activities of daily living in older peop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okui, Nobuo, Ikegami, Tadashi, Hashimoto, Tatsuo, Kouno, Yuko, Nakano, Kaori, Okui, Machiko Aurora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Urology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387135/ https://www.ncbi.nlm.nih.gov/pubmed/37525863 http://dx.doi.org/10.7759/cureus.42668

Ejemplares similares

Laser Treatment for Patients With Vulvodynia and Interstitial Cystitis/Bladder Pain Syndrome: A Case Series (The UNICORN-3 Study)
por: Okui, Nobuo, et al.
Publicado: (2023)

Long-Term Improvement in Urinary Incontinence in an Elite Female Athlete Through the Laser Treatment: A Case Report
por: Okui, Nobuo, et al.
Publicado: (2023)

Efficacy of Two Laser Treatment Strategies for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
por: Okui, Nobuo, et al.
Publicado: (2023)

Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
por: Rohrsted, Malene, et al.
Publicado: (2012)

Ninjin’yoeito Improves Genitourinary Symptoms in Patients With Frailty
por: Okui, Nobuo, et al.
Publicado: (2023)

Is Erbium/Neodymium Laser Combination Therapy an Effective Treatment Option for Interstitial Cystitis/Bladder Pain Syndrome With Vulvodynia?
por: Okui, Nobuo, et al.
Publicado: (2022)

Analysis of Predictive Factors for Return to Sports in Female Athletes With Stress Urinary Incontinence
por: Okui, Nobuo, et al.
Publicado: (2023)

Impact of depression on overactive bladder
por: Kawahara, Takashi, et al.
Publicado: (2020)

Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists
por: Okui, Nobuo
Publicado: (2019)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation
por: Trinh, Hamilton, et al.
Publicado: (2019)

Risk factors associated with the progression of overactive bladder among patients with type 2 diabetes
por: Zhu, Yiyi, et al.
Publicado: (2019)

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
por: Wyndaele, J-J, et al.
Publicado: (2009)

Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence
por: Wyman, J F, et al.
Publicado: (2009)

Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder
por: Lee, L. K., et al.
Publicado: (2015)

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)
por: Drake, Marcus J., et al.
Publicado: (2017)

A novel approach to overactive bladder syndrome treatment
por: Szalecki, Paweł
Publicado: (2014)

Mechanism of traditional Chinese medicine in treating overactive bladder
por: Liao, Yuxiang, et al.
Publicado: (2022)

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria
por: Matsumoto, Seiji, et al.
Publicado: (2013)

Sleep disturbance changes in women after treatment of refractory overactive bladder with sacral neuromodulation
por: Sanderson, Derrick J., et al.
Publicado: (2020)

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
por: Nitti, V W, et al.
Publicado: (2013)

A comparison of normal and high post-void residual urine and urodynamic parameters in women with overactive bladder
por: Dağdeviren, Hediye, et al.
Publicado: (2017)

Detrusor-Overactivity-Related Voiding in Women Mimics Bladder Outflow Obstruction and Conceals Underactivity
por: Kitta, Takeya, et al.
Publicado: (2023)

Editorial Comment: Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature
por: Riccetto, Cássio L. Z.
Publicado: (2021)

Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain
por: Crespo, Carlos, et al.
Publicado: (2018)

Friction underwear for ease of pulling down in elderly patients with overactive bladder: A prospective randomized control trial
por: You, Jae Hyung, et al.
Publicado: (2019)

The role of intra‐operative void score during transurethral resection of prostate as a marker of efficacy: a feasibility study
por: Robinson, Christian, et al.
Publicado: (2022)

Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study
por: El-Dakhakhny, Amr S., et al.
Publicado: (2019)

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study
por: Hawken, Natalia, et al.
Publicado: (2016)

Posterior tibial nerve stimulation as treatment for the overactive bladder
por: Sherif, Hammouda, et al.
Publicado: (2013)

High efficacy of biofeedback therapy for treatment of dysfunctional voiding in children
por: Krzemińska, Katarzyna, et al.
Publicado: (2012)

Validation of the Arabic linguistic version of the Overactive Bladder Symptoms Score questionnaire
por: Elbaset, M. A., et al.
Publicado: (2019)

Comparison of urethral sling surgery and non-ablative vaginal Erbium:YAG laser treatment in 327 patients with stress urinary incontinence: a case-matching analysis
por: Okui, Nobuo, et al.
Publicado: (2021)

Editorial Comment: Optimal timing of a second postoperative voiding trial in women with incomplete bladder emptying after vaginal reconstructive surgery: a randomized trial
por: Riccetto, Cássio L. Z.
Publicado: (2021)

Evaluation of female overactive bladder using urodynamics: relationship with female voiding dysfunction
por: Cho, Kang Jun, et al.
Publicado: (2015)

TASCI—transcutaneous tibial nerve stimulation in patients with acute spinal cord injury to prevent neurogenic detrusor overactivity: protocol for a nationwide, randomised, sham-controlled, double-blind clinical trial
por: Birkhäuser, Veronika, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_recqus915mk5fbm72uldadtetc